Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

A 84-month follow up of adherence to HAART in a cohort of adult Senegalese patients.

Etard JF, Lanièce I, Fall MB, Cilote V, Blazejewski L, Diop K, Desclaux A, Ecochard R, Ndoye I, Delaporte E; ANRS 1215/1290 Study Group.

Trop Med Int Health. 2007 Oct;12(10):1191-8.

2.

Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.

Etard JF, Ndiaye I, Thierry-Mieg M, Guèye NF, Guèye PM, Lanièce I, Dieng AB, Diouf A, Laurent C, Mboup S, Sow PS, Delaporte E.

AIDS. 2006 May 12;20(8):1181-9.

PMID:
16691070
3.

Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults.

Laurent C, Ngom Gueye NF, Ndour CT, Gueye PM, Diouf M, Diakhaté N, Touré Kane NC, Lanièce I, Ndir A, Vergne L, Ndoye I, Mboup S, Sow PS, Delaporte E; ANRS 1215/1290 Study Group.

J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):14-7.

PMID:
15608518
4.

Adherence to HAART and its principal determinants in a cohort of Senegalese adults.

Lanièce I, Ciss M, Desclaux A, Diop K, Mbodj F, Ndiaye B, Sylla O, Delaporte E, Ndoye I.

AIDS. 2003 Jul;17 Suppl 3:S103-8.

PMID:
14565616
5.

Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.

Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, Montaner JS.

AIDS. 2008 Nov 12;22(17):2371-80. doi: 10.1097/QAD.0b013e328315cdd3.

PMID:
18981777
6.

Revisiting long-term adherence to highly active antiretroviral therapy in Senegal using latent class analysis.

Bastard M, Fall MB, Lanièce I, Taverne B, Desclaux A, Ecochard R, Sow PS, Delaporte E, Etard JF.

J Acquir Immune Defic Syndr. 2011 May 1;57(1):55-61. doi: 10.1097/QAI.0b013e318211b43b.

PMID:
21775934
7.

Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data.

Protopopescu C, Raffi F, Roux P, Reynes J, Dellamonica P, Spire B, Leport C, Carrieri MP; ANRS CO8 APROCO-COPILOTE Study Group.

J Antimicrob Chemother. 2009 Sep;64(3):599-606. doi: 10.1093/jac/dkp232. Epub 2009 Jul 14.

PMID:
19602563
8.

Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients.

Horberg MA, Silverberg MJ, Hurley LB, Towner WJ, Klein DB, Bersoff-Matcha S, Weinberg WG, Antoniskis D, Mogyoros M, Dodge WT, Dobrinich R, Quesenberry CP, Kovach DA.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):384-90.

PMID:
18091609
9.

Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study.

Carrieri MP, Raffi F, Lewden C, Sobel A, Michelet C, Cailleton V, Chêne G, Leport C, Moatti JP, Spire B; APROCO study group.

Antivir Ther. 2003 Dec;8(6):585-94.

PMID:
14760892
10.

Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults.

Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, Chaisson RE, Maartens G.

J Acquir Immune Defic Syndr. 2006 Sep;43(1):78-84.

PMID:
16878045
11.

Field adherence to highly active antiretroviral therapy in HIV-infected adults in Abidjan, Côte d'Ivoire.

Eholié SP, Tanon A, Polneau S, Ouiminga M, Djadji A, Kangah-Koffi C, Diakité N, Anglaret X, Kakou A, Bissagnené E.

J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):355-8.

PMID:
17438479
12.

Modeling CD4+ cell count increase over a six-year period in HIV-1-infected patients on highly active antiretroviral therapy in Senegal.

De Beaudrap P, Etard JF, Diouf A, Ndiaye I, Guèye NF, Guèye PM, Sow PS, Mboup S, Ndoye I, Ecochard R, Eric D; ANRS 1215/90 Study Group.

Am J Trop Med Hyg. 2009 Jun;80(6):1047-53.

PMID:
19478274
13.

Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.

Roux P, Carrieri MP, Cohen J, Ravaux I, Poizot-Martin I, Dellamonica P, Spire B.

Clin Infect Dis. 2009 Nov 1;49(9):1433-40. doi: 10.1086/630209.

PMID:
19807275
14.

Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.

León A, Martinez E, Milinkovic A, Mora B, Mallolas J, Blanco JL, Larrousse M, Laguno M, Gallart T, Plana M, Gatell JM, Garcia F.

J Antimicrob Chemother. 2009 Jan;63(1):184-8. doi: 10.1093/jac/dkn461. Epub 2008 Nov 11.

PMID:
19001447
15.

Adherence to highly active antiretroviral therapy in HIV-infected inmates.

Inés SM, Moralejo L, Marcos M, Fuertes A, Luna G.

Curr HIV Res. 2008 Mar;6(2):164-70.

PMID:
18336264
16.

The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.

Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, Spire B; MANIF2000 cohort study group.

Addiction. 2008 Nov;103(11):1828-36. doi: 10.1111/j.1360-0443.2008.02323.x. Epub 2008 Sep 4.

PMID:
18778390
17.

Effectiveness of antiretroviral treatment in a South African program: a cohort study.

Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, Steyn D, Staniland GH, Timmerman V, Msimanga M, Seebregts CJ, Boulle A, Nhiwatiwa R, Bateman ED, Zwarenstein MF, Chapman RD.

Arch Intern Med. 2008 Jan 14;168(1):86-93. doi: 10.1001/archinternmed.2007.10.

PMID:
18195200
18.
19.

Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.

Lima VD, Gill VS, Yip B, Hogg RS, Montaner JS, Harrigan PR.

J Infect Dis. 2008 Jul 1;198(1):51-8. doi: 10.1086/588675.

PMID:
18498238
20.

Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.

Golub ET, Benning L, Sharma A, Gandhi M, Cohen MH, Young M, Gange SJ.

Clin Infect Dis. 2008 Jan 15;46(2):305-12. doi: 10.1086/524752.

PMID:
18171267

Supplemental Content

Support Center